Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603168 | 0.83 | LMNA (0.42) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL19442049 | 0.81 | HTT (0.58) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL7070609 | 0.81 | TDP1 (0.38) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL6229622 | 0.79 | TDP1 (0.51) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL7138575 | 0.79 | ALDH1A1 (0.65) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL18407151 | 0.78 | TDP1 (0.50) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL4892995 | 0.78 | TDP1 (0.68) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL31462928 | 0.77 | ALDH1A1 (0.63) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL38726 | 0.75 | TDP1 (0.61) | KMT2ATDP1MEN1ALDH1A1HPGD | |
| SCHEMBL11904537 | 0.75 | TDP1 (0.61) | KMT2ATDP1MEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | claimed |
| CN-114773298-B | Preparation method of 2, 5-disubstituted furan compound | 中国科学院宁波材料技术与工程研究所 | 2024-09-20 | — | — | CN | disclosed |
| EP-4251621-A1 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230286969-A1 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116390920-A | Aromatic spirocyclic amide derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114773299-A | Preparation method of 2, 5-disubstituted furan compound | 中国科学院宁波材料技术与工程研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-114773298-A | Preparation method of 2, 5-disubstituted furan compound | 中国科学院宁波材料技术与工程研究所 | 2022-07-22 | — | — | CN | disclosed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | disclosed |
| WO-2005074875-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-02 | — | — | US | disclosed |
| EP-1409464-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003008389-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | WO | disclosed |
| US-4634783-A | ENZYME INHIBITORS, ANTICOMPLEMENT AGENT | TORII & CO. LTD. (JP) | 1987-01-06 | — | — | US | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | PDK4, OXA1L, PPARD | KMT2A 4151/4885TDP1 2252/4885MEN1 2846/4885 |
| US-20230286969-A1 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1H4, SLC10A1 | KMT2A 2189/4885TDP1 4377/4885MEN1 2062/4885 |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, CYB5R3 | KMT2A 1179/4885TDP1 3239/4885MEN1 4871/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KMT2A 1569/4885TDP1 1059/4885MEN1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.